MedTrace Logo

Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)

NCT05953337 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-03-04

No results posted yet for this study

Summary

This is a prospective, multi-center, open-label study to evaluate the effectiveness and safety of Eye90 microspheres® in the treatment of subjects with unresectable Hepatocellular Carcinoma (HCC). Eye90 microspheres is a medical device containing yttrium-90 (Y-90), a radioactive material, and provides local radiation brachytherapy for the treatment of liver tumors.

Conditions

Interventions

DEVICE

EYE90 Microspheres Treatment

Y90 glass microspheres

Sponsors & Collaborators

  • ABK Biomedical

    lead INDUSTRY

Principal Investigators

  • Andrew Kennedy, MD · Director, Radiation Oncology Research at Sarah Cannon

  • Ammar Sarwar, MD · Director of Radiation Oncology Research, Beth Israel Deaconess Medical Center

  • Aravind Arepally, MD · ABK Biomedical, Inc

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-21
Primary Completion
2027-02-28
Completion
2027-02-28
FDA Device
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05953337 on ClinicalTrials.gov